Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife has recently announced the signing of a Letter of Intent (LOI) with a leading industry partner, Hipro Biotechnology, as a component of its B2B strategy to enter key markets with the Egoo Health system. Qlife is now pleased to announce the signing of a collaboration agreement.
The agreement in brief
The agreement consists of four major parts:
1. Integration of reagents
2. Regulatory approval from the China Food and Drug Administration for Egoo Health
3. Distribution and sales of Egoo Health to Chinese hospitals
4. Production of Egoo Health
Integration of Reagents
The collaboration between Qlife and Hipro Biotechnology marks a significant advancement in the capabilities of the Egoo Health platform. The current reagents from Hipro Biotechnology are compatible and will be integrated with the Egoo Health platform. This strategic integration is set to expand the Egoo Health testing portfolio extensively, paving the way for a comprehensive test menu.
Regulatory Approval
Hipro Biotechnology will start and lead the regulatory process to secure approvals from the China Food and Drug Administration (CFDA) for Egoo Health. The process consists of approvals of the Egoo Health software and hardware, and Hipro Biotechnology will solely cover all costs related to the approval.
Distribution and sales of Egoo Health to Chinese Hospitals
Hipro Biotechnology, a leading point-of-care diagnostics company with an extensive distribution network to more than 14,000 Chinese hospitals, will be responsible for the marketing, sales, and distribution of Egoo Health to Chinese hospitals. Hipro Biotechnology will solely cover associated costs and Qlife will receive royalties for products sold. Hipro is forecasting into the millions of Egoo tests sold during first full year expected to be 2025.
Production of Egoo Health
Hipro Biotechnology will initially focus on the production of EgooCapsules and EgooCollect blood-to-plasma units. The production of Egoo instrument will remain in Scandinavia until the relationship has fully matured.
CEO, Thomas Warthoe comments on the agreement:
"We are highly satisfied with this first agreement with Hipro Biotechnology. With this agreement, our newly launched strategy of entering major markets through partnerships to tap into the hospital-at-home concept is crystallizing. We believe the match between Qlife and Hipro Biotechnology is unparalleled, as we have the unique software and hardware and Hipro Biotechnology has the expertise of approval, sales, and a position as an already established major player in China.
The integration of reagents allows for a fast and intensive expansion of tests, and we expect that the CFDA-approval in China will support and speed up the process for our CE-marking process in Europe."
Qlife's Expansion Strategy
This collaboration with Hipro Biotechnology is the materialization of the first step in Qlife's strategic plan to establish a foothold in major markets such as the USA, China, India, UK, and Japan. Recognizing the diverse healthcare infrastructure across these major nations and European countries, Qlife will focus on forming partnerships with well-established entities in these countries to ensure the effective deployment of Egoo for Hospital-at-Home.
About Hipro Biotechnology
Hipro Biotechnology Corp, founded in 2006, is a leading point-of-care company in China with sales to more than 14.000 hospital in China. The company provide first-in-class products to its customers in China and other parts of the world. Hipro focuses on R&D, manufacturing, marketing, and relevant services of Point-of-Care products. Hipro has production bases in Hebei Province, Beijing, Suzhou, Chengdu, Guangzhou, and recently launched 3.69 acres industrial park project in China Medical City. Furthermore, the company has an R&D Center in Silicon Valley, USA and instrument R&D Center in Freiburg, Germany.